Purpose: There is considerable interest in positive allosteric modulators (PAMs) of the α-amino-3-hydroxyl-5-methyl-4-isoxazole-propionate (AMPA) subtype of ionotropic glutamate receptors as therapeutic agents for a range of cognitive and mood disorders. However, the challenge is to increase AMPA receptor (AMPAR) function sufficient to enhance cognitive function but not to the extent that there are mechanism-related pro-convulsant or convulsant side effects. In this present study, we report the preclinical pharmacology data for MDI-222, an AMPAR PAM which enhances cognition but has a much reduced side-effect (i.e. convulsant) liability relative to other molecules of this mechanism. Methods: The pharmacological effects of MDI-222 were characterised in in vitro and in vivo preclinical electrophysiology, efficacy (cognition), sideeffect (pro-convulsant/convulsant), tolerability and toxicity assays. Results: We demonstrate that MDI-222 is an AMPAR PAM, since it enhanced AMPAR function in vitro at human (hGluA1-4) and rat (rGluA2) homomeric receptors, and potentiated hetero-oligomeric AMPARs in rat neurons. MDI-222 enhanced electrically evoked AMPAR-mediated synaptic transmission in the anaesthetised rat at 10 mg/kg (administered intravenously) and did not significantly lower the seizure threshold in the pro-convulsant maximal electroshock threshold test (MEST) at any dose tested up to a maximum of 30 mg/kg (administered by oral gavage (p.o.)). MDI-222 reversed a delayinduced deficit in novel object recognition (NOR) in rats with a minimum effective dose (MED) of 0.3 mg/kg (p.o.) following acute administration, which was reduced to 0.1 mg/kg following sub-chronic administration, and improved passive avoidance performance in scopolamine-impaired rats with a MED of 10 mg/kg p.o. On the other hand, MDI-222 was not pro-convulsant in the MEST, resulting in a therapeutic window between plasma concentrations that enhanced cognitive performance and those associated with mechanism-related side effects of ⩾1000-fold. Unfortunately, despite the excellent preclinical profile of this compound, further development had to be halted due to non-mechanism-related issues.
Introduction
There is growing evidence to implicate a dysfunction in glutamate neurotransmission, and the α-amino-3-hydroxy-5-methyl-4isoxazolepropionic acid (AMPA) subtype of ionotropic glutamate receptors (iGluRs) in particular, in the pathophysiology of a variety of central nervous system disorders (Chang et al., 2012; Dauvermann et al., 2017; Lee et al., 2016) . More specifically, AMPA receptors (AMPARs) play a critical role in synaptic function, since their activation by glutamate results in a depolarisation of the postsynaptic membrane which relieves the voltage-dependent Mg 2+ -blockade of N-methyl-D-aspartate receptors (NMDARs; Huganir and Nicoll, 2013) . In addition, AMPARs are trafficked into and out of the synapse in a use-dependent manner, underscoring the importance of these receptors in synaptic plasticity (Henley and Wilkinson, 2016) .
Given their importance in the physiology and pathology of synapses, it is of little surprise that AMPARs have attracted considerable attention as potential therapeutic targets (Partin, 2015; Reuillon et al., 2016; Ward et al., , 2015 Black, 2005) . For example, a reduction in the activity of AMPARs by non-competitive antagonists such as talampanel (GYKI 537773, LY300164) and perampanel are effective in a variety of preclinical anticonvulsant models, with the latter being approved as an antiepileptic drug under the brand name Fycompa (Tsai et al., 2018) . On the other hand, the well-established role of AMPAR in synaptic plasticity and the nootropic actions of the weak AMPA-potentiating effects of aniracetam (Ito et al., 1990; Tang et al., 1991) have resulted in the increase in AMPAR function being pursued as a very attractive approach to improving cognitive performance in a variety of disorders (Chang et al., 2012) . In this regard, a wide range of AMPAR positive allosteric modulators (PAMs) have been described, of which several from Cortex Pharmaceuticals (CX516, CX614, CX691, also known as ORG24448 and farampator, CX717, CX1739) and individual molecules from Eli Lilly (LY451395), Organon (ORG26576), Pfizer (PF-04958242), Servier (S18986 and S47445), GSK (GSK729327) and Takeda have entered clinical studies. However, none has yet achieved regulatory approval, with the development of these various compounds being halted for a variety of molecule-or mechanism-specific properties such as short half-life, insufficient potency, poor tolerability or inability to dose high enough to achieve sufficient exposure (Buccafusco, 2009; Purcell et al., 2018; Reuillon et al., 2016) .
One of the primary concerns with modulating AMPAR function is the potential for mechanism-related pro-convulsant or convulsant liability. Hence, in the same way that negative allosteric modulators of AMPARs such as peramapanel are anticonvulsant, then so potentiating AMPARs can promote excitotoxicity and/or seizures. This is of particular concern for the so-called Class I (or high-impact) AMPAR PAMs, which alter the kinetics of AMPAR-mediated receptor deactivation and desensitisation to enhance and prolong synaptic currents (Arai and Kessler, 2007) . On the other hand, Class II (low-impact) AMPAR PAMs only affect deactivation and therefore have a much reduced effect on synaptic currents compared with Class I AMPAR PAMs (Arai and Kessler, 2007) .
In a previous paper, we described the properties of UoS12258, a Class I AMPAR PAM which progressed into clinical studies. In single-dose (0.25-1.75 mg) studies in humans, this compound had a long half-life (~130 hours), and clinical development was halted due to the risk of drug accumulation beyond the limits established by the preclinical convulsant liability in rats, dogs and monkeys (Ward et al., 2017) . In the present paper, we describe the properties of MDI-222 (Ward et al., 2011) , a back-up compound with a pyrazole chemotype distinct from that of the lead sulphonamide compound UoS12258 (Figure 1 ). Hence, MDI-222 is a Class II AMPAR PAM (Ward et al., 2011 ) that enhances cognition but has a much reduced convulsant liability relative to its predecessor. Unfortunately, the preclinical development of this compound was halted due to issues unrelated to the AMPAR PAM mechanism. Nevertheless, this compound serves as an example of an AMPAR PAM with a much improved safety profile relative to others within this class.
Materials and methods
The biological assay methods are described in more detail elsewhere (Ward et al., 2017) . All animal studies were ethically reviewed and carried out in accordance with Animals (Scientific Procedures) Act 1986 and the GSK Policy on the Care, Welfare and Treatment of Animals.
Compound MDI-222 ( Figure 1 ) has a molecular weight of 363 and polar surface area of 38 Å 2 , and the preparation and preliminary characterisation of this compound have been described previously (Ward et al., 2011) . The compound has generally good brain penetration, with a ratio of brain:plasma drug concentration in the region of 1.5, and has binding to rat, dog, monkey and human plasma protein and rat brain protein of ⩾99%. The respective plasma half-life and oral bioavailability values were 1.4 hours and 54% in rats and 1.3 hours and 18% in dogs.
Intracellular Ca 2+ influx assay
Homomeric human GluA1 flip isoform (hGluA1i), hGluA3i and hGluA4i and rat GluA2i AMPAR were all transiently transfected into HEK-293 cells using appropriate DNA constructs (all Q-unedited in TM2 region to allow Ca 2+ permeability) and a Lipofectamine 2000 system, whereas hGluA2i AMPAR were stably expressed in HEK293 cells. Cells were seeded onto 384-well poly-D-lysine-coated plates (black with a clear bottom; Greiner Bio-One, Kremsmünster, Austria) at a density of 7500 cells/well two days prior to assay.
Heteromeric hGluN1A/GluN2B NMDARs were produced by transfection of HEK-293 cells with a mixture of hGluN1A-BacMam and hGluN2B-BacMam expression vectors. Cells were incubated with 500 µM of the non-competitive NMDAR antagonist ketamine hydrochloride after which the BacMam vectors were washed away and cells were plated onto poly-D-lysine coated black/clear plates at a density of 20,000 cells/well, again in the presence of 500 µM ketamine, and incubated for 24 hours prior to the assay. Homomeric hGluK1 kainate receptors were produced by the transient transfection of HEK-293 cells with human GRIK1 (Q/unedited) using the Lipofectamine 2000 method. Human GluK2 receptors were stably expressed in HEK cells. Cells were seeded onto 384-well plates at a density of 7500 cells/well 24 hours prior to assay.
The general method for intracellular Ca 2+ measurements was that on the day of the assay, cells were washed three times with assay buffer (20 mM HEPES, 145 mM NaCl, 5 mM KCl, 1 mM MgCl 2 , 2 mM CaCl 2 , 5.5 mM glucose, pH 7.3 with NaOH) after which 20 µL was added to each well. Fluo-4AM (20 µL) was then added to each well (final assay concentration = 2 µM; Molecular Probes, Eugene, OR), and plates were incubated for 60 minutes in the dark. Cell plates were then washed three times to remove unloaded Fluo-4, and 30 µL of assay buffer was added to each well, and compound added in a 1:3 serial dilution using a dual 10 µL compound + 10 µL agonist (glutamate, final assay concentration = 100 µM) addition protocol. Fluorescence intensity was measured using a Fluorescent Imaging Plate Reader (FLIPR) instrument, and LY404187 was included in each plate as a reference compound.
Recombinant receptor electrophysiology
hGluA2 cells were plated onto poly-D-lysine-coated microscope slide coverslips (BD Biosciences, Franklin Lakes, NJ) at a density of 50-75,000 cells/mL and used one or two days later. Whole-cell currents were recorded using the perforated patchclamp technique with an EPC9 or EPC10 patch-clamp system and the Pulse program (HEKA Instruments, Inc., Holliston, MA). External and internal recording solutions comprised 140 mM NaCl, 2 mM KCl, 1 mM MgCl 2 , 2 mM CaCl 2 , 10 mM glucose and 12 mM HEPES, pH 7.35, and 150 mM CsCl, 10 mM EGTA and 10 mM HEPES, pH 7.3, respectively. Patch pipettes had resistances of 2-5 MΩ, and solution exchange was achieved by using the RSC-160 (Bio-Logic Science Instruments, Seyssinet-Pariset, France) fast perfusion system to produce a rapid application of glutamate. Cells were clamped at -60 mV, the current induced by a two-second application of agonist was recorded and agonist application was repeated every 30 seconds in the absence or presence of test compound. Compound responses were related to the current produced by 1 mM alone.
Native receptor electrophysiology
Embryonic rat brains were harvested following sacrifice of the pregnant female by CO 2 inhalation. The dissected hippocampi were placed into ice-cold medium comprised of Hank's Balanced Salt Solution (HBSS; Ca 2+ -and Mg 2+ -free), 1 mM pyruvate, 100 mg/mL penicillin, 100 mg/mL streptomycin, 10 mM HEPES, and 0.035% NaHCO 3 , and tissue was then trypsinized for 30 minutes at 37°C in trypsin/EDTA diluted (final concentration 0.05%) in HBSS with sodium pyruvate (Ca 2+ -and Mg 2+ -free). Tissue pieces were physically dissociated, and neurons were plated onto poly-D-lysine-coated coverslips in plating medium (Neurobasal Medium + 1 mM sodium pyruvate, 100 mg/mL penicillin, 100 mg/mL streptomycin, 1× B27 supplement, 1 mM L-glutamine), and cells were used for recordings after 5-13 days in culture.
Whole-cell voltage-clamp recordings from rat cultured hippocampal neurons were made using standard methods and an Axopatch 200B amplifier and pClamp v8.0 software (Axon Instruments ® ; Molecular Devices, San Jose, CA), with cells being held at -70 mV throughout. Solution exchange was achieved using a fast-step two-tube perfusion system (RSC-160; Bio-Logic).
Inward currents induced by AMPA application were complex in that their magnitude and duration depended on three different mechanisms: (a) opening of the AMPA receptor channel measured in terms of peak amplitude, (b) desensitisation of AMPA receptors measured as the degree of relaxation of the inward current from its initial peak amplitude to a reduced steady-state plateau level in the continued presence of AMPA and (c) deactivation of AMPA receptors measured as the rate at which the inward current decayed back to baseline following termination of the AMPA application. For each of these parameters, the effects of MDI-222 were compared with the effects of AMPA alone.
In vivo electrophysiology
Surgery was performed on adult male Lister hooded rats (240-340 g) under isoflurane anaesthesia and involved cannulating the jugular vein using Portex tubing such that the cannula projected externally from the animal. Each rat was then placed in a stereotaxic frame, with body temperature being maintained using a thermostatically controlled heated blanket and rectal probe. A midline incision was made to expose the dorsal aspect of the skull and a burr hole made to allow implantation of a concentric bipolar stimulating electrode (World Precision Instruments, Sarasota, FL) into the medial perforant pathway (from lambda: AP 0 mm, ML 4.0-4.2 mm, DV ~2.5-2.8 mm). A small craniotomy was made and the dura reflected to allow a tungsten recording electrode (0.1 MΩ; World Precision Instruments) to be implanted into the ipsilateral dentate gyrus (from bregma: AP -3.6 mm, ML 2.0-2.55 mm, DV ~2.5-3.0 mm).
Recordings were made with reference to a silver ground electrode placed under the skin margin, and potentials were amplified and filtered using a NeuroLog™ extracellular AC recording system (gain 200; filters 0.1 Hz to 3 kHz). A linear constant stimulus isolator driven by Spike2 software, and a CED pulse shaper was used to deliver electrical stimuli (<50% maximum; duration 90-200 µs) through the concentric bipolar stimulating electrode at either 0.1 or 0.03 Hz. Stable field excitatory postsynaptic potentials (fEPSPs) and superimposed population spikes were recorded in response to each stimulus, with a paired-pulse stimulation paradigm being used to verify electrode placement. Once stable responses were established, a baseline set of responses was recorded for a 20-minutes period after which vehicle (99% polyethylene glycol 200/1% dimethyl sulfoxide doses at 1 mL/kg) or MDI-222 were administered via the jugular vein cannula and recordings made for a 20-minutes period. The study was then terminated, and blood and brain samples were collected and frozen at -80°C prior to subsequent analysis of drug concentrations using liquid chromatography/tandem mass spectrometry using a Micromass Quattro Premier (Wilmslow, UK) mass spectrometer with positive-ion electrospray ionisation.
Novel object recognition
Rats were habituated to Perspex test arenas (42 cm long × 21 cm wide × 20 cm high) for 60 minutes in the morning and three minutes in the afternoon on two consecutive days prior to testing. Rats were sham dosed with vehicle prior to both one-hour habituation sessions. On the first test day, rats were placed in a test arena for a three-minute habituation period and then presented with two identical objects (T1, 3 minutes). Twenty-four hours later, rats were placed back in the test arena and presented with one of the previous (familiar) objects and a novel object (T2, 3 minutes). Objects used were similar-sized black plastic tower and pyramid shapes (~6.5 cm high × 6 cm wide). Objects were cleaned with 70% ethanol between animals to remove any odour trace. The novel object and novel object side (left or right) was randomised equally across all treatment groups. The time spent exploring the objects during T1 and T2 was recorded by an observer blind to the novel object.
Rats (n = 12/group) received MDI-222 or vehicle (1% methylcellulose) by oral gavage (p.o.) unless stated otherwise. For the acute study, MDI-222 was administered at 0.1, 0.3, 1 and 3 mg/kg p.o. 30 minutes prior to testing in both T1 and T2 sessions. For the sub-chronic study, MDI-222 was administered at 0.03, 0.1, 0.3 and 1 mg/kg p.o. once daily for seven days and then 30 minutes prior to T1 and T2 sessions on days 8 and 9, respectively. Immediately after T2 behavioural testing, rats (n = 3 for all treatment groups) were culled, and blood and brains were taken for pharmacokinetic analysis, as described previously.
The key parameters derived from the novel object recognition (NOR) assay are the T1 and T2 times, which are the total time spent exploring both objects during Trial 1 and Trial 2, respectively. The D1 index is the time spent exploring the novel object during Trial 2 minus the time spent exploring the familiar object during Trial 2, whereas the D2 index is the D1 index/total exploration time during Trial 2 (T2). Of these different parameters, the D2 index is used as the primary indicator of an ability to 'remember' the objects experienced during Trial 1. Hence, a larger D2 index in drug-treated relative to vehicle-treated animals represents an increased ability to 'remember' the objects experienced during Trial 1.
Passive avoidance
The passive avoidance task (PA) records the ability of animals to remember an aversive stimulus. Performance is impaired by post-training treatment with the muscarinic antagonist scopolamine. Male Wistar rats were pretreated with MDI-222 30 minutes prior to training (3, 10 and 30 mg/kg p.o. in 25% labrasol; n = 6). Scopolamine (1 mg/kg administered intraperitoneally (i.p.)) was given six hours post training. Task recall was assessed 24 hours post training in the absence of drug.
Maximal electroshock threshold test
Half an hour before testing, male Lister Hooded rats (118-145 g; n = 12/group) received i.p. injections of either saline or the known pro-convulsant picrotoxin (2 mg/kg i.p.), or p.o. doses of either vehicle (1% methylcellulose) or 3, 10 or 30 mg/kg MDI-222. During the testing phase, the induction of a tonic hind-limb extensor seizure was assessed following a 0.1-second shock administered via corneal electrodes according to the 'up and down' method (Kimball et al., 1957) . A separate (satellite) group of animals (n = 2/3 per dose) were dosed, and blood and brain samples were taken at the appropriate pretreatment time for analysis of compound.
Results

MDI-222 potentiates Ca 2+ flux in recombinant homomeric AMPARs
In cells stably expressing hGluA2 AMPAR, the application of glutamate (100 µM) alone did not elicit a signal due to rapid AMPAR desensitisation. However, in the presence of MDI-222, the application of glutamate consistently increased intracellular Ca 2+ levels to a maximum extent (123 ± 7%) comparable with the positive control (LY404187; Table 1 ). The effect of MDI-222 in hGluA2 AMPAR was concentration dependent and had a pEC 50 of 5.3 (EC 50 = 5.0 µM) that was comparable with UoS12258 (pEC 50 = 5.19, EC 50 = 6.5 µM; Ward et al., 2017) .
MDI-222 had comparable effects at all four homomeric human AMPAR subtypes (i.e. GluA1, GluA2, GluA3 and GluA4) and showed no marked differences between rats and humans GluA2 AMPARs (Table 1 ). There were no effects of MDI-222 on glutamate-induced currents in cell lines expressing either GluN1A/GluN2B-containing NMDARs or GluK1 or GluK2 kainate receptors measured either using the Ca 2+ flux assay or whole-cell patch-clamp electrophysiology (data not shown). The selectivity of MDI-222 for AMPAR was further emphasised by the fact that when tested at a concentration of 10 µM, it demonstrated no significant binding to a panel of 79 different receptors, ion channels and transporters (CEREP).
MDI-222 potentiates whole-cell glutamateinduced currents in hGluA2 AMPARs
The functional effects of MDI-222 on hGluA2 AMPARs were further assessed using whole-cell voltage-clamp electrophysiology to measure potentiation of inward currents evoked by 1 mM glutamate (Figure 2 ). MDI-222 significantly potentiated glutamate-evoked charge transfer (area under the curve) by 121 ± 7% (p < 0.05, paired t-test, n = 9) at 100 nM and 702 ± 40% at 10 µM (p < 0.05, paired t-test, n = 3).
MDI-222 potentiates AMPAR-mediated responses in native rat AMPARs
The effect on native neuronal AMPARs was assessed by measuring the effects of 1 nM to 10 μM MDI-222 on AMPA-induced whole-cell currents (30 μM, two-second pulses every 30 seconds) recorded from rat cultured hippocampal neurons. Representative current traces from a neuron incubated with AMPA alone or AMPA + 10 nM or 10 μM MDI-222 are overlaid in Figure 3 . The potentiation of AMPA-induced currents was quantified in terms of the effects of MDI-222 on total charge 5.3 ± 0.1 (9) 123 ± 7 (9) hGluA3i
4.5 ± 0.1 (3) 53 ± 3 (3) hGluA4i
5.1 ± 0.1 (4) 76 ± 1 (4) rGluA2i
5.4 ± 0.1 (4) 76 ± 8 (4) Values shown are the mean ± standard error of the mean for experiments with more than 2 measurements (individual measurements shown for n=2 experiment). a The maximum response is defined in terms of the positive control LY404187. b MDI-222 was tested four times and gave a consistent max response (30 ± 2%), but it was only possible to calculate pEC 50 values reliably in 2/4 assays. AMPAR: α-amino-3-hydroxyl-5-methyl-4-isoxazole-propionate receptor transfer (essentially the area under the curve), and the rates of desensitisation and deactivation. These parameters are summarised in Table 2 which clearly shows a significant but modest effect on charge transfer and desensitisation at minimum effective concentrations of 1 and 10 nM, respectively. However, there was no effect on deactivation except at the highest concentration tested (10 µM). As regards total charge transfer, 10 µM MDI-222 gave only a modest (62%) increase in the charge transfer.
In order to demonstrate that MDI-222 could modulate electrophysiological activity in vivo, anaesthetised rats were given either 3 or 10 mg/kg compound intravenously (i.v.), and the amplitude of the electrically evoked dentate gyrus population spike was measured. Figure 4 shows that a 10 (but not 3) mg/kg i.v. dose of MDI-222 was able to increase population spike amplitude significantly from 70% of baseline in the vehicletreated animals to 139% of baseline (p < 0.05, n = 3). Analysis µM AMPA-induced current by 10 nM and 10 µM MDI-222 in cultured isolated rat hippocampal neurons. Importantly, when applied in the absence of AMPA, MDI-222 did not invoke an inward current, indicating that it needed the presence of agonist to be effective. (5) 1.14 ± 0.05* 0.77 ± 0.10 1.06 ± 0.04 10 nM (4) 1.37 ± 0.09* 0.81 ± 0.05* 1.19 ± 0.15 100 nM (4) 1.33 ± 0.12* 0.76 ± 0.03* 1.29 ± 0.17 1 µM (4) 1.28 ± 0.14* 0.72 ± 0.04* 1.33 ± 0.17 10 µM (9) 1.62 ± 0.15* 0.25 ± 0.08* 2.79 ± 0.43* Values shown are the mean ± standard error of the mean. MDI-222 potentiates the dentate gyrus population spike amplitude in anaesthetised rats. * Statistically significant changes compared with AMPA alone (*p < 0.05 paired t-test). Figure 4 . MDI-222 (10 mg/kg intravenously (i.v.)) was able to increase the amplitude of the electrically evoked population spike recorded in the dentate gyrus of anaesthetised rats (the 30% reduction in amplitude within the vehicle group relative to baseline is presumed to be related to the i.v. injection). Veh.: vehicle (99% polyethylene glycol 200/1% dimethyl sulfoxide). Values shown are the mean ± standard error of the mean (SEM; n = 3/group). of brain samples taken immediately after the experiment showed mean brain drug concentrations of 11.6 µg/g.
NOR
Two separate acute, single-dose administration studies of the effects of MDI-222 in the NOR assay were conducted. In experiment 1, doses of 0.1, 0.3 and 1 (but not 3) mg/kg p.o. MDI-222 resulted in a significant increase in the time spent exploring the novel relative to familiar objects ( Figure 5(a) , left-hand panel). This translated into a significant increase the D2 index at 0.3 and 1 mg/kg (but not 0.1 or 3) mg/kg ( Figure 5(a) , right-hand panel). In experiment 2, p.o. doses of 0.3, 1 and 3 mg/kg all produced a significant increase both in the exploration of the novel relative to familiar object and the D2 index ( Figure 5(b) ). At the minimal effective dose for the D2 index of 0.3 mg/kg, the respective mean blood and brain drug concentrations were 9 ng/mL and 16 ng/g for experiment 1 and 25 ng/mL and 37 ng/g for experiment 2, with the differences between experiments presumably reflecting a variability in the formulation of the compound that was a consequence of its poor solubility. When administered sub-chronically for seven days, MDI-222 significantly increased the exploration of the novel versus familiar object at doses of 0.1, 0.3 and 1 mg/kg p.o., with these same three doses also significantly increasing the D2 index ( Figure 5(c) ). At the minimally effective dose of 0.1 mg/kg, mean blood and brain levels were 7 ng/mL and 9 ng/g, respectively.
MDI-222 reverses a scopolamine-induced deficit in passive avoidance
Compared with vehicle-treated animals, scopolamine (1 mg/kg i.p.) produced a much shorter latency for rats to step through from the safe to the aversive chamber ( Figure 6 ; respective latencies for vehicle-and scopolamine-treated rats = 457 ± 83 seconds and 157 ± 46 seconds), indicating that scopolamine impairs the 'remembering' of the conditioning trial on day 1. Doses of 10 and 30 mg/kg p.o. MDI-222 were able to reverse the scopolamine-induced deficit significantly. These effects could not be attributed to changes in exploratory behaviour, since on either the training or recall day, activity in the open field was not altered by drug treatment (data not shown). Accordingly, in this assay, the minimum effective dose (MED) of MDI-222 was 10 mg/kg p.o.
MDI-222 is not pro-convulsant in the maximal electroshock seizure threshold test
In the maximal electroshock threshold test (MEST) test, corneal application of electrical current (CC 50 ~60-70 mA, 0.1 ms duration) in the rat induces tonic and full tonic-clonic seizures. As expected, the GABA A receptor blocker picrotoxin produced a robust pro-convulsant effect, reducing the CC 50 by almost half relative to saline-treated controls (CC 50 values of 49 ± 8 and 26 ± 1 for saline and picrotoxin-treated animals, respectively; Figure 7) . In contrast, MDI-222 did not significantly affect the seizure threshold, with CC 50 values (53 ± 2, 51 ± 4 and 52 ± 2 at 3, 10 and 30 mg/kg p.o., respectively) being between 10% and 15% lower than vehicle (1% methylcellulose)-treated rats (CC 50 = 60 ± 4). This lack of effect of MDI-222 was despite excellent brain exposures (measured in a satellite group of animals), with the highest dose tested, 30 mg/kg p.o., resulting in brain drug concentrations of ~4700 ng/g.
Discussion
MDI-222 is a relatively weak and non-selective potentiator of the human AMPAR as measured using the Ca 2+ flux assay (pEC 50 values ranging from 4.5 to 5.4 across the hGluA1, hGluA2, hGluA2 and hGluA2 subtypes). Moreover, there were no humanto-rat species differences, since the pEC 50 values of MDI-222 at hGluA2 and rGluA2 were comparable (pEC 50 values of 5.3 and 5.4, respectively). The compound did not have activity at other members of the iGluR family, demonstrating no effects on GluN1a/GluN2B heteromeric NMDARs or homomeric GluK1 or GluK2 receptors in either the Ca 2+ flux or electrophysiological assays. In addition, MDI-222 did not bind a panel of 70 different receptors, ion channels and transporters, further emphasising its selectivity for AMPARs. MDI-222 was the back-up compound to the lead molecule UoS12258 (Ward et al., 2017) . This latter compound was also a relatively weak AMPAR PAM, having a pEC 50 of 5.6 in both the Ca 2+ flux and whole-cell patch clamp assays but was much more potent that MDI-222, with, for example, the maximal potentiation in the charge transfer (i.e. area under the curve) in rat primary hippocampal neurons being 62% for MDI-222 (Table 2) and 310% for UoS12258 (Ward et al., 2017) .
The apparently modest in vitro AMPA PAM efficacy of MDI-222 nevertheless translated into a significant functional effect in vivo in that MDI-222 was able to potentiate the dentate gyrus population spike amplitude in anaesthetised rats (Figure 3 ) and enhanced cognitive performance in the NOR assay, with minimum effective doses of 0.3 and 0.1 mg/kg p.o. when dosed Figure 6 . MDI-222 reversed a scopolamine-induced deficit in performance in the rat passive avoidance assay. Vehicles used were saline (scopolamine, given intraperitoneally (i.p.)) and 1% methyl cellulose . Values shown are the mean ± SEM (n = 6/group). *p < 0.05 versus the veh. + scopolamine group. Figure 7 . MDI-222 does not reduce seizure threshold in the maximal electroshock seizure threshold test. MDI-222 was dosed orally in a 1% methylcellulose vehicle with a pretreatment time of 0.5 h prior to testing. In these studies, the effects of picrotoxin (Ptx, 2 mg/kg i.p.) versus animals treated with saline (Sal) were used as a positive control. Values shown are the mean ± SEM (n = 12/group), with a satellite group of animals (n = 2-3/dose) being dosed in order to generate blood and drug concentrations. **p < 0.01 compared with vehicle-treated animals.
acutely and sub-chronically, respectively (Figure 4) . The MED for MDI-222 in the acute-dosing NOR assay is the same as that obtained for the 'more potent' UoS12258 (0.3 mg/kg p.o.). However, the MED of UoS12258 in the NOR following subchronic dosing (0.01 mg/kg p.o.; Ward et al., 2017) was appreciably lower than that seen with MDI-222 (0.1 mg/kg p.o.). On the other hand, in the rat passive avoidance assay, both MDI-222 and UoS12258 were able to reverse a scopolamine-induced deficit with similar MED values (10 and 3 mg/kg p.o., respectively). Hence, despite their differences in intrinsic efficacy, both MDI-222 (a low-impact AMPAR PAM) and UoS12258 (a high-impact AMPAR PAM) have a broadly similar potency with respect to cognitive enhancement. In contrast, the compounds had markedly different effects in the MEST assay of pro-convulsant activity. Hence, MDI-222 had no effect on the seizure threshold, even at a dose (30 mg/kg p.o.) that gave excellent brain exposure with drug concentrations of ~4.7 µg/g (Figure 7 ). In contrast, UoS12258 produced a marked reduction in the threshold such that at a dose (100 mg/kg p.o.) giving a brain exposure of ~5.0 µg/g, the pro-convulsant effect was comparable with that of the positive control picrotoxin (Ward et al., 2017) .
Despite possessing a pro-convulsant activity in the MEST assay, UoS12258 progressed into preclinical and clinical development, since at the time this was considered to be an inherent, mechanism-related side effect that could not be separated out from the cognition-enhancing effects. Furthermore, in six-week Good Laboratory Practice (GLP) preclinical safety and toxicity studies, UoS12258 demonstrated convulsant activity in all three species studied (rat, dog and cynomolgus monkey), with the no adverse effect levels being defined at 2.5 and 3 mg/kg p.o. for the cynomolgus monkey and rat, respectively (Figure 8 ). Thereafter, UoS12258 was evaluated in single-dose (0.25-1.75 mg) Phase I studies in humans where further development was halted due to a prolonged half-life (~130 hours), which raised the possibility of drug accumulation to levels beyond those considered acceptable from a safety point of view.
In contrast to UoS12258, MDI-222 had a much more benign preclinical safety profile. Specifically, and consistent with its lack of a pro-convulsant liability in the MEST assay, in seven-day doserange study, doses of up to 1600 mg/kg in rats (corresponding to plasma C max concentrations of ~15,000 ng/mL) and 1000 mg/kg in dogs (4-8000 ng/mL, depending on gender) were well tolerated and did not produce convulsions (Figure 8 ). There were also no convulsions observed in the subsequent four-week GLP safety assessment studies in either rats or dogs, even at the highest doses tested (800 mg/kg in rat and 1000 mg/kg in dog, corresponding to respective plasma C max concentrations of 13-17,000 and 8-13,000 ng/mL).
During the four-week safety assessment studies, systemic exposures on day 28 relative to day 1 were up to sixfold lower in rats and ninefold lower in dogs, and non-dose-proportional o. and neither did it cause convulsions during seven-day dose ranging studies (maximum doses in rat and dog = 1600 and 1000 mg/kg p.o., respectively) or four-week Good Laboratory Practice (GLP) safety and toxicity studies (maximum doses in rat and dog = 800 and 1000 mg/kg p.o., respectively). To overcome solubility-limiting subproportional concentrations at higher doses, 14-day exploratory toxicity studies were conducted using a nanomilled formulation. In plasma drug concentrations equivalent to a dose of ~2000 mg/kg of the standard formulation, convulsions were observed. (b) UoS12258 was pro-convulsant in the MEST assay at a dose of 10 mg/kg p.o. (data not shown for clarity; Ward et al., 2017) and during dose-range studies caused convulsions in dogs, cynomolgus (cyno.) monkeys and rats at doses of 3, 9 and 10 mg/kg p.o., respectively. Because of the sensitivity of dogs, the cynomolgus monkey was chosen as the second species, along with the rat, for six-week GLP safety and toxicity studies in which convulsions were observed at doses of 4 and 10 mg/kg in cynomolgus monkeys and rats, respectively, with the no adverse effect levels being 2.5 and 7.5 mg/kg, respectively. For both compounds, the efficacy assay used to define the therapeutic margin was the novel object recognition assay. Doses shown are mg/kg p.o. systemic concentrations were observed at elevated doses. To improve systemic concentrations and investigate the potential metabolic induction, an additional 14-day exploratory toxicity investigation was conducted. In these studies, dogs were dosed with a nanomilled formulation of MDI-222 that produced a plasma exposure (C max = 23,000 ng/mL) equivalent to ~2000 mg/ kg of the 'standard' formulation, and convulsions were observed.
Given that the minimal effective dose of MDI-222 in the NOR assay is either 0.3 mg/kg p.o. when dosed acutely (corresponding to plasma drug concentrations of 9 and 25 ng/mL in experiments 1 and 2, respectively) or 0.1 mg/kg p.o. when given sub-chronically (plasma concentration = 7 ng/mL), there is a very large ⩾1000-fold therapeutic index between plasma concentrations required for efficacy (7-25 ng/mL) and those shown to cause convulsions in dogs (23,000 ng/mL). Despite this very attractive safety profile, further development of MDI-222 was halted due to non-mechanism-related development issues. These included poor solubility, high protein binding and an activation of the pregnane X receptor linked to a potential for drug-drug interactions.
In summary, MDI-222 is an AMPAR PAM which produced cognition-enhancing effects in rats with a significantly improved tolerability profile over its predecessor UoS12258 and other molecules of this class. Although further development of MDI-222 was not possible, these studies nevertheless demonstrate the feasibility of dissociating the desirable cognition enhancing effects from the unwanted pro-convulsant or convulsant liabilities that are often considered to be inherent in compounds that enhance AMPAR-mediated neurotransmission. The dissociation between the cognition enhancing and pro-convulsant/convulsant effects as a consequence of increasing AMPAR function has also recently been demonstrated with additional compounds (Kunugi et al., 2019) and suggests that the therapeutic potential of AMPAR PAMs may finally achieve clinical utility, not only in diseases associated with cognitive dysfunction, but also in other disorders associated with a dysfunction of glutamatergic neurotransmission and more specifically AMPARs, such as depression (Zanos et al., 2016) .
